Overview

Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with schizophrenia who are at risk for diabetes.
Phase:
Phase 4
Details
Lead Sponsor:
Veterans Medical Research Foundation
Collaborators:
National Institute of Mental Health (NIMH)
Pfizer
Treatments:
Antipsychotic Agents
Insulin
Olanzapine
Risperidone
Ziprasidone